SFM Investors Have Opportunity to Lead Sprouts Farmers Market, Inc. Securities Fraud Lawsuit

PR Newswire

NEW YORK, Dec. 26, 2025 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities and sellers of put options of Sprouts Farmers Market, Inc. (NASDAQ: SFM) between June 4, 2025 and October 29, 2025, both dates inclusive (the “Class Period”), of the important January 26, 2026 lead plaintiff deadline.

So what: If you purchased Sprouts securities and/or sold put options during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Sprouts class action, go to https://rosenlegal.com/submit-form/?case_id=48630 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 26, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants provided investors with material information concerning Sprouts’ growth potential for the fiscal year 2025. Defendants’ statements included, among other things, confidence in Sprouts’ customer base to remain resilient to macroeconomic pressures and that Sprouts would instead benefit from the perceived tailwinds from a more cautious consumer. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Sprouts’ growth potential; notably, that a more cautious consumer could result in significant slowdown in sales growth and the purported tailwinds would be unable to dampen the slowdown or would otherwise fail to manifest entirely. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Sprouts class action, go to https://rosenlegal.com/submit-form/?case_id=48630 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sfm-investors-have-opportunity-to-lead-sprouts-farmers-market-inc-securities-fraud-lawsuit-302649746.html

SOURCE THE ROSEN LAW FIRM, P. A.

MEDIROM Partners with World

Deploying “Proof of Human” Infrastructure throughout Japan, a Technology Envisioned by Sam Altman and Alex Blania

TOKYO, Dec. 26, 2025 (GLOBE NEWSWIRE) — MEDIROM Healthcare Technologies Inc. (Headquarters:Minato-ku, Tokyo; CEO: Kouji Eguchi; NASDAQ: MRM, MEDIROM or the “Company”), a diversified healthcare company, is collaborating with World Foundation and Tools for Humanity to deploy Proof of Human technologies such as World ID throughout Japan. The World project was co-created by Sam Altman and Alex Blania.

In preparation for the full-scale rollout of the World project in Japan, MEDIROM has entered into a Master Service Agreement (“MSA”) with Tools for Humanity (“TFH”) and World Foundation (“WF”). Under the MSA, the MEDIROM Group will be responsible for the operation of “Proof of Human” verification locations in Japan. This initiative is expected to contribute to MEDIROM’s revenue through operation fees and related services over time. Leveraging MEDIROM’s nationwide network of approximately 300 physical locations and operational expertise, the collaboration enables rapid and trusted deployment of Proof of Human technology at scale. To support this effort, MEDIROM will newly establish a dedicated special task force, the “MEDIROM World Proof of Human Task Force,” and will strengthen its organizational structure to promote the nationwide rollout of Proof of Human technology powered by World.

■ Background and Purpose of the 
Collaboration

In recent years, advances in generative AI have made it extremely difficult to distinguish between “humans” and “AI” online, creating a global challenge to establish trust online. To address this challenge, Sam Altman and Alex Blania co-created World. World aims to provide a mechanism, utilizing blockchain technology, that allows anyone worldwide to safely and fairly prove they are human (“Proof of Human”) without revealing their identity.

MEDIROM shares this vision and established a special task force, the “MEDIROM World Proof of Human Task Force.”

The Company will begin full-scale collaboration in Japan with TFH and WF to bring the World Proof of Human verification technology to people throughout Japan. MEDIROM will drive access across diverse fields beyond its existing footprint of relaxation and wellness retail locations. The Company expects such expansion to contribute to a future where everyone can participate in the digital society with confidence through the social implementation of “Proof of Human.”

■ Key Initiatives

・Availability of Orbs, an advanced camera deploying privacy-preserving technologies to verify humanness, in approximately 300 Re.Ra.Ku Group locations
・Establishment and operation of flagship locations offering Proof of Human verification services
・Deployment of Proof of Human verification pop-up stores in commercial facilities and public spaces

◼︎
Comment from Koji Eguchi, President and CEO of MEDIROM

We are excited to launch this collaboration in Japan with Tools for Humanity and World Foundation. As generative AI rapidly permeates society, we firmly believe that this new social infrastructure for “proving one’s humanness” will become an indispensable foundation for the future digital society.

Through this collaboration, we seek to broaden our reach with new approaches, such as establishing flagship locations and pop-up stores, to build an authentication environment that more people can use with confidence. We intend not only to grow this initiative into a new revenue model but also to contribute to building trust within Japan’s digital society, further accelerating our evolution as a health tech company.

■ Comment from Tomoe Makino, General Manager of Japan at Tools For Humanity

“Japan has long been a global leader in adopting technology that improves everyday life, and we believe Proof of Human will become essential digital infrastructure in the age of AI,” said Tomoe Makino, General Manager of Tools for Humanity Japan. “By collaborating with MEDIROM, which has deep roots in communities across the country, we can bring World ID to people in trusted, familiar spaces and support a future where everyone can participate in the digital society with greater confidence.”

■ About Tools for Humanity

Tools for Humanity (TFH) is a global technology company established to build for humans in the age of AI. Founded by Sam Altman and Alex Blania, it led the initial development of World Network and operates World App. Tools for Humanity Corporation is headquartered in San Francisco, California and Munich, Germany. To learn more, visit: toolsforhumanity.com


About World Network

World is intended to be the world’s largest, most inclusive network of real humans. The project was originally conceived by Sam Altman, Max Novendstern, and Alex Blania and aims to provide Proof of Human, finance and connection for every human in the age of AI. Find out more about World at world.org and on X.

◼︎
About MEDIROM Group

MEDIROM Group operates approximately 300 wellness salons under the “Re.Ra.Ku®” brand nationwide. Since 2015, we have expanded into HealthTech, offering on-demand training apps like Lav® for specific health guidance and lifestyle improvement programs. In 2020, we started manufacturing the 24/7 recharge-free smart tracker “MOTHER Bracelet®,” which is now used in REMONY, our remote monitoring system for various industries including caregiving, transportation, construction, and manufacturing.

About MEDIROM Healthcare Technologies Inc.
NASDAQ Symbol: MRM
Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan
Web https://medirom.co.jp/en
Contact: [email protected]

■ Forward-Looking Statements Regarding MEDIROM

Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about MEDIROM’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to MEDIROM’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause MEDIROM’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond MEDIROM’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects MEDIROM’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to MEDIROM’s operations, results of operations, growth strategy and liquidity. Some of the factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release include:

・ A third party entering into a letter agreement with TFH and WF and the MSA becoming effective;

・ MEDIROM’s ability to achieve its development goals for its business and execute and evolve its growth strategies, priorities and initiatives;

・changes in Japanese and global economic conditions and financial markets, including their effects on MEDIROM’s expansion in Japan and certain overseas markets;

・ MEDIROM’s ability to achieve and sustain profitability in its Digital Preventative Healthcare Segment;

・ the fluctuation of foreign exchange rates, which affects MEDIROM’s expenses and liabilities payable in foreign currencies;

・ MEDIROM’s ability to maintain and enhance the value of its brands and to enforce and maintain its trademarks and protect its other intellectual property;

・ MEDIROM’s ability to raise additional capital on acceptable terms or at all;

・ MEDIROM’s level of indebtedness and potential restrictions on MEDIROM under MEDIROM’s debt instruments;

・ changes in consumer preferences and MEDIROM’s competitive environment;

・ MEDIROM’s ability to respond to natural disasters, such as earthquakes and tsunamis, and to global pandemics, such as COVID-19; and

・ the regulatory environment in which MEDIROM operates.

More information on these risks and other potential factors that could affect MEDIROM’s business, reputation, results of operations, financial condition, and stock price is included in MEDIROM’s filings with the Securities and Exchange Commission (the “SEC”), including in the “Risk Factors” and “Operating and Financial Review and Prospects” sections of MEDIROM’s most recently filed periodic report on Form 20-F and subsequent filings, which are available on the SEC website at www.sec.gov. MEDIROM assumes no obligation to update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/0b2181b2-369c-4c34-b8f6-81c70c1fd4a5

https://www.globenewswire.com/NewsRoom/AttachmentNg/7fe8345a-89ae-4b3a-8936-9baa15d8a488

https://www.globenewswire.com/NewsRoom/AttachmentNg/327df9bf-e3fd-4488-80dd-034a30fd8d61

https://www.globenewswire.com/NewsRoom/AttachmentNg/6e842344-f6c8-4149-a163-9e15547d2f1c



Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)

NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) — Southpoint Capital Advisors LP (“Southpoint”), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on December 24, 2025, pursuant to securities laws, it disposed of beneficial ownership of 1,000,000 common shares (a “Common Share”) of Fennec Pharmaceuticals Inc. (“Fennec”), representing approximately 2.93% of the outstanding Common Shares (calculated on a fully diluted basis).

The Common Shares were sold at a price of USD$7.50 per Common Share.

Southpoint now exercises control or direction over an aggregate of 2.7 million Common Shares, and representing approximately 8% of the outstanding Common Shares (calculated on a fully diluted basis).

Southpoint has disposed of the Common Shares for investment purposes. Depending on market and other conditions, Southpoint may change its beneficial ownership of, or control or direction over, Common Shares through market transactions, private agreements, treasury issuances, exercise of the Warrants or otherwise.

This press release has been issued in order to comply with applicable securities legislation.



For further information: 
Anthony J. Buffalano III
Southpoint Capital Advisors LP
1114 Avenue of the Americas, 22nd Floor
New York, NY 10036
Phone: (212) 692-6356

Outlook Therapeutics Announces New Employment Inducement Grants

ISELIN, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that effective December 19, 2025, the Outlook Therapeutics, Inc. Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 150,000 shares of Outlook Therapeutics common stock with a per share exercise price of $2.01 per share to two new employees.

The above-described awards were granted as an inducement material to the employees entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retinal diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD (wet age-related macular degeneration). Outlook Therapeutics commenced the commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the treatment of wet AMD.

In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.

Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
[email protected]



DeFi Technologies Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before January 30, 2026 to Discuss Your Rights – DEFT

NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in DeFi Technologies (“DeFi Technologies” or the “Company”) (NASDAQ: DEFT) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DeFi Technologies investors who were adversely affected by alleged securities fraud between May 12, 2025 and November 14, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/defi-technologies-lawsuit-submission-form?prid=181421&wire=3

DEFT investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) DeFi Technologies was facing delays in executing its DeFi arbitrage strategy, which at all relevant times was a key revenue driver for the Company; (ii) DeFi Technologies had understated the extent of competition it faced from other digital asset treasury companies and the extent to which that competition would negatively impact its ability to execute its DeFi arbitrage strategy; (iii) as a result of the foregoing issues, the Company was unlikely to meet its previously issued revenue guidance for the fiscal year 2025; (iv) accordingly, defendants had downplayed the true scope and severity of the negative impact that the foregoing issues were having on DeFi Technologies’ business and financial results; and (v) as a result, defendants’ public statements were materially false and misleading at all relevant times.

WHAT’S NEXT? If you suffered a loss in DeFi Technologies during the relevant time frame, you have until January 30, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com



Class Action Filed Against Coupang, Inc. (CPNG) – February 17, 2026 Deadline to Join – Contact Levi & Korsinsky

NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Coupang, Inc. (“Coupang, Inc.” or the “Company”) (NYSE: CPNG) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Coupang, Inc. investors who were adversely affected by alleged securities fraud between August 6, 2025 and December 16, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/coupang-inc-lawsuit-submission-form?prid=181422&wire=3

CPNG investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Coupang had inadequate cybersecurity protocols that allowed a former employee to access sensitive customer information for nearly six months without being detected; (2) this subjected Coupang to a materially heightened risk of regulatory and legal scrutiny; (3) When defendants became aware that Coupang had been subjected to this data breach, they did not report it in a current report filing (to be filed with the U.S. Securities and Exchange Commission (the “SEC”)) in compliance with applicable reporting rules; and (4) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

WHAT’S NEXT? If you suffered a loss in Coupang, Inc. during the relevant time frame, you have until February 17, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected] 
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com 



Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Blue Owl Capital Inc.(OWL) Shareholders

NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Blue Owl Capital Inc. (“Blue Owl Capital Inc.” or the “Company”) (NYSE: OWL) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Blue Owl Capital Inc. investors who were adversely affected by alleged securities fraud between February 6, 2025 and November 16, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/blue-owl-capital-inc-lawsuit-submission-form?prid=181419&wire=3

OWL investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Blue Owl was experiencing a meaningful pressure on its asset base from business development companies’ redemptions; (2) as a result, the Company was facing undisclosed liquidity issues; (3) as a result, the Company would be likely to limit or halt redemptions of certain business development companies; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT’S NEXT? If you suffered a loss in Blue Owl Capital Inc. during the relevant time frame, you have until February 2, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected] 
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com 



Telix Pharmaceuticals Ltd. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights – TLX

NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. (“Telix Pharmaceuticals Ltd.” or the “Company”) (NASDAQ: TLX) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/telix-pharmaceuticals-ltd-lawsuit-submission-form?prid=181417&wire=3

TLX investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates; (2) defendants materially overstated the quality of Telix’s supply chain and partners; and (3) as a result, defendants’ statements about Telix’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

WHAT’S NEXT? If you suffered a loss in Telix Pharmaceuticals Ltd. during the relevant time frame, you have until January 9, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com



StubHub Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – STUB

NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in StubHub Holdings, Inc. (“StubHub Holdings, Inc.” or the “Company”) (NYSE: STUB) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of StubHub Holdings, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons and entities that purchased or otherwise acquired StubHub common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s September 2025 initial public offering. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/stubhub-holdings-inc-lawsuit-submission-form?prid=181420&wire=3

STUB investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) the Company was experiencing changes in the timing of payments to vendors; (2) those changes had a significant adverse impact on free cash flow, including trailing 12 months free cash flow; (3) as a result, the Company’s free cash flow reports were materially misleading; and (4) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

WHAT’S NEXT? If you suffered a loss in StubHub Holdings, Inc. during the relevant time frame, you have until January 23, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com



Levi & Korsinsky Reminds Perrigo Company plc Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2026 – PRGO

NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Perrigo Company plc (“Perrigo Company plc” or the “Company”) (NYSE: PRGO) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Perrigo Company plc investors who were adversely affected by alleged securities fraud between February 27, 2023 and November 4, 2025. Follow the link below to get more information and be contacted by a member of our team:


https://zlk.com/pslra-1/perrigo-company-plc-lawsuit-submission-form?prid=181416&wire=3
 

PRGO investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) the infant formula business acquired from Nestlé suffered from significant underinvestment in maintenance, operational improvements, and repairs; (2) Perrigo needed to make substantial capital and operational expenditures above the Company’s outwardly stated cost estimates to remediate the infant formula business; (3) there were significant manufacturing deficiencies in the facility for the Company’s infant formula business; (4) as a result of the foregoing, the Company’s financial results, including earnings and cash flow, were overstated; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT’S NEXT? If you suffered a loss in Perrigo Company plc during the relevant time frame, you have until January 16, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com